Six-month triptorelin depot injection now available

As Decapeptyl SR 22.5mg is a suspension of microparticles, intravascular injection must be strictly avoided
As Decapeptyl SR 22.5mg is a suspension of microparticles, intravascular injection must be strictly avoided

Ipsen has added a six-month triptorelin depot injection to its Decapeptyl SR range.

The 22.5mg presentation is licensed for the treatment of metastatic prostate cancer and for locally advanced, non-metastatic prostate cancer as an alternative to surgical castration.

It is supplied as a powder and solvent for suspension, to be administered by intramuscular injection.

Decapeptyl SR is also available in 1-monthly (3mg) and 3-monthly (11.25mg) presentations for the treatment of precocious puberty and endometriosis.

View Decapeptyl SR drug record

Further information: Ipsen

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases